MX367046B - Marcadores especificos de via para diagnosticar sindrome del intestino irritable. - Google Patents
Marcadores especificos de via para diagnosticar sindrome del intestino irritable.Info
- Publication number
- MX367046B MX367046B MX2015016196A MX2015016196A MX367046B MX 367046 B MX367046 B MX 367046B MX 2015016196 A MX2015016196 A MX 2015016196A MX 2015016196 A MX2015016196 A MX 2015016196A MX 367046 B MX367046 B MX 367046B
- Authority
- MX
- Mexico
- Prior art keywords
- bowel syndrome
- irritable bowel
- specific markers
- pathway specific
- ibs
- Prior art date
Links
- 208000002551 irritable bowel syndrome Diseases 0.000 title abstract 5
- 230000037361 pathway Effects 0.000 title 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 208000015943 Coeliac disease Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827506P | 2013-05-24 | 2013-05-24 | |
| PCT/IB2014/061636 WO2014188378A1 (en) | 2013-05-24 | 2014-05-22 | Pathway specific markers for diagnosing irritable bowel syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX367046B true MX367046B (es) | 2019-08-02 |
Family
ID=50884973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016196A MX367046B (es) | 2013-05-24 | 2014-05-22 | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9891235B2 (enExample) |
| EP (2) | EP3004892B1 (enExample) |
| JP (4) | JP2016520199A (enExample) |
| KR (2) | KR20160010621A (enExample) |
| CN (2) | CN105579852B (enExample) |
| AU (3) | AU2014269961A1 (enExample) |
| BR (2) | BR112015029320A8 (enExample) |
| CA (2) | CA2912993A1 (enExample) |
| HK (1) | HK1223361A1 (enExample) |
| IL (2) | IL242597B (enExample) |
| MX (1) | MX367046B (enExample) |
| RU (2) | RU2015155552A (enExample) |
| SG (2) | SG11201509371XA (enExample) |
| WO (2) | WO2014188378A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2912993A1 (en) | 2013-05-24 | 2014-11-27 | Nestec S.A. | Pathway specific markers for diagnosing irritable bowel syndrome |
| CN119236063A (zh) | 2013-06-21 | 2025-01-03 | 翁德克控股有限公司 | 免疫治疗组合物及其用途 |
| KR20170005058A (ko) * | 2014-05-09 | 2017-01-11 | 노그라 파마 리미티드 | 염증성 장 질환을 치료하는 방법 |
| TWI690536B (zh) | 2014-11-19 | 2020-04-11 | 英商Ｎｚｐ英國有限公司 | 化合物（一） |
| CA2968338A1 (en) | 2014-11-19 | 2016-05-26 | Nestec S.A. | Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof |
| CN107108687B (zh) | 2014-11-19 | 2019-10-29 | Nzp英国有限公司 | 作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇 |
| KR102546748B1 (ko) | 2014-11-19 | 2023-06-22 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드 |
| CA2968310A1 (en) | 2014-11-19 | 2016-05-26 | NZP UK Limited | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| WO2016088068A1 (en) * | 2014-12-02 | 2016-06-09 | Nestec S.A. | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
| CN105987995A (zh) * | 2015-02-04 | 2016-10-05 | 东莞博捷生物科技有限公司 | 一种检测人抗酿酒酵母IgG类抗体的酶联免疫试剂盒 |
| CN105987996A (zh) * | 2015-02-09 | 2016-10-05 | 东莞博捷生物科技有限公司 | 一种检测人抗酿酒酵母IgA类抗体的酶联免疫试剂盒 |
| CN105061305A (zh) * | 2015-08-31 | 2015-11-18 | 河南师范大学 | 一步合成3-甲基-2-吡啶甲酸甲酯的方法 |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CN106399344B (zh) * | 2016-06-01 | 2021-01-01 | 上海领潮生物新材料有限公司 | 一种vin-cdtb融合蛋白的制备方法 |
| WO2018011691A1 (en) * | 2016-07-12 | 2018-01-18 | Nestec S.A. | Competitive immunoassay methods |
| CN106188191A (zh) * | 2016-07-13 | 2016-12-07 | 西安电子科技大学 | 基于gsh响应的诊治一体化有机分子探针及其制备方法 |
| US11959125B2 (en) | 2016-09-15 | 2024-04-16 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| US10428370B2 (en) | 2016-09-15 | 2019-10-01 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| KR20190047023A (ko) * | 2016-09-15 | 2019-05-07 | 썬 제노믹스 인코포레이티드 | 샘플에서 1종 이상의 유형의 다양한 미생물 집단으로부터 핵산 분자를 추출하는 범용 방법 |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3554362A4 (en) * | 2016-12-14 | 2020-08-12 | Warren, Tracy | SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH |
| EP3554344A1 (en) | 2016-12-14 | 2019-10-23 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
| WO2018112235A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| EP3554346B1 (en) | 2016-12-14 | 2024-01-31 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| CA3046093A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| KR20190095931A (ko) | 2016-12-14 | 2019-08-16 | 프로제너티, 인크. | 섭취가능한 디바이스를 사용하여 방출된 il-12/il-23 저해제로의 위장관 질환의 치료 |
| WO2018112245A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
| WO2018112240A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| MX2019006867A (es) | 2016-12-14 | 2020-01-13 | Progenity Inc | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de integrina. |
| US11978543B2 (en) | 2016-12-14 | 2024-05-07 | Astarte Medical Partners Inc. | System and methods for developing and using a microbiome-based action component |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| CA3054947A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with live biotherapeutics |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2018183931A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist |
| CA3054159A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
| WO2019036363A1 (en) | 2017-08-14 | 2019-02-21 | Progenity Inc. | TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| EP3750168B1 (en) * | 2018-02-09 | 2025-11-19 | Metabolomic Diagnostics Limited | A system and method of generating a model to detect, or predict the risk of, an outcome |
| KR102699211B1 (ko) * | 2018-03-19 | 2024-08-26 | 후지필름 가부시키가이샤 | 정신 질환의 판정 방법 |
| EP3785033B1 (en) * | 2018-04-24 | 2025-12-10 | Universiteit Gent | Intestinal biomarkers for intestinal health of poultry |
| JP7421504B2 (ja) | 2018-06-01 | 2024-01-24 | ビオラ・セラピューティクス・インコーポレイテッド | 胃腸のマイクロバイオームの検出および操作のためのデバイスおよびシステム |
| AU2019281024A1 (en) * | 2018-06-07 | 2020-12-24 | 4D Pharma Plc | Method for stratifying IBS patients |
| CN110607335B (zh) * | 2018-06-14 | 2021-08-03 | 中国科学院微生物研究所 | 一种烟酰胺腺嘌呤二核苷酸类化合物生物合成方法 |
| CN109324132A (zh) * | 2018-10-31 | 2019-02-12 | 杭州佰辰医学检验所有限公司 | 高通量检测色氨酸及其代谢产物的试剂盒及其应用 |
| US11488699B1 (en) | 2018-12-09 | 2022-11-01 | Cerner Innovation, Inc. | Microbiota activity sensor and decision support tool |
| US11842795B1 (en) * | 2018-12-17 | 2023-12-12 | Cerner Innovation, Inc. | Irritable bowel syndrome diagnostic sensor and decision support tool |
| FR3094492A1 (fr) * | 2019-04-01 | 2020-10-02 | Polyneuros | Procédé de détection ou de suivi de l’évolution d’une maladie chronique dégénérative par dosage immunologique |
| WO2020201457A1 (en) * | 2019-04-03 | 2020-10-08 | 4D Pharma Cork Limited | Methods of diagnosing disease |
| WO2020213732A1 (ja) * | 2019-04-18 | 2020-10-22 | 株式会社サイキンソー | 過敏性腸症候群の検査方法 |
| US11884958B2 (en) * | 2019-04-30 | 2024-01-30 | Mayo Foundation For Medical Education And Research | Assessing and treating functional gastrointestinal disorders |
| EP3969621A4 (en) | 2019-05-14 | 2023-01-25 | Prometheus Biosciences, Inc. | TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES |
| WO2020232262A1 (en) * | 2019-05-16 | 2020-11-19 | Procisedx Inc. | Assay detection methods for vcam-1 and calprotectin |
| CN111351870A (zh) * | 2019-12-03 | 2020-06-30 | 康美华大基因技术有限公司 | 一种肠易激综合征血清代谢标记物组合及其诊断试剂盒 |
| EP4085256B1 (en) | 2020-01-27 | 2024-01-24 | Immundiagnostik AG | Test and in vitro diagnosis of irritable bowel syndrome |
| WO2021152586A1 (en) * | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Methods of analyzing microbiome, immunoglobulin profile and physiological state |
| EP3913371A1 (en) | 2020-05-18 | 2021-11-24 | Neuroimmun GmbH | Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions |
| KR102478205B1 (ko) * | 2020-09-24 | 2022-12-15 | 경희대학교 산학협력단 | 크론병 환자에서 상부위장관 침범 진단을 위한 정보 제공 방법 |
| CN114755313B (zh) * | 2021-01-08 | 2024-08-30 | 复旦大学附属华山医院 | 包含尿液nad+代谢物的急性肾损伤标志物 |
| CN115724779B (zh) * | 2021-09-01 | 2024-03-29 | 四川大学 | 酰胺烷二硫化合物、其制备方法和用途 |
| WO2023122320A1 (en) * | 2021-12-24 | 2023-06-29 | Kuleon Llc | Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists |
| WO2023180899A1 (en) * | 2022-03-21 | 2023-09-28 | Swain Manish Kumar | Device and method for detecting diarrhea |
| CN116381222A (zh) * | 2023-03-23 | 2023-07-04 | 北京巴瑞医疗器械有限公司 | 一种血清素发光免疫检测方法及血清素检测试剂盒 |
| CN116990498B (zh) * | 2023-09-28 | 2024-08-09 | 山东大学齐鲁医院 | 血浆色氨酸代谢物在儿童偏头痛诊断中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6218129B1 (en) * | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| CN1423656A (zh) * | 1999-12-15 | 2003-06-11 | 卡比斯特制药公司 | 作为抗菌剂的脂肽 |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| DE10121217A1 (de) * | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
| WO2005041896A2 (en) | 2003-11-03 | 2005-05-12 | Duke University | Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| US20060154276A1 (en) * | 2004-05-13 | 2006-07-13 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US20060019410A1 (en) | 2004-07-21 | 2006-01-26 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
| WO2007000046A1 (en) * | 2005-06-27 | 2007-01-04 | Holburn Biomedical Corporation | Methods for diagnosing functional bowel disease |
| US7873479B2 (en) | 2005-12-01 | 2011-01-18 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US20100094560A1 (en) | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US8278057B2 (en) | 2007-09-14 | 2012-10-02 | Nestec S.A. | Addressable antibody arrays and methods of use |
| BRPI1013560A2 (pt) | 2009-04-14 | 2018-06-19 | Prometheus Laboratories Inc | métodos para auxiliar no prognóstico de doença instestinal inflamatória, e para predizer a probabilidade que um indivíduo diagnosticado com doença intestinal inflamatória responderá a um agente terapêutico de doença intestinal inflamatória |
| US20120171672A1 (en) | 2009-04-14 | 2012-07-05 | Prometheus Laboratories Inc. | Inflammatory bowel disease prognostics |
| AU2010266028B2 (en) | 2009-06-25 | 2015-04-30 | Société des Produits Nestlé S.A. | Methods for diagnosing irritable bowel syndrome |
| WO2011053831A1 (en) * | 2009-10-30 | 2011-05-05 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| CA2781654A1 (en) * | 2009-11-25 | 2011-06-03 | Hua Gong | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| US8445215B1 (en) * | 2010-07-23 | 2013-05-21 | Nestec S.A. | Assays and methods for the detection of Crohn's disease |
| WO2012158831A1 (en) * | 2011-05-16 | 2012-11-22 | Prometheus Laboratories Inc. | Performance of a biomarker panel for irritable bowel syndrome |
| JP2015502740A (ja) * | 2011-10-21 | 2015-01-29 | ネステク ソシエテ アノニム | 炎症性腸疾患の診断を改善するための方法 |
| CA2886991A1 (en) | 2012-10-05 | 2014-04-10 | Nestec S.A. | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs |
| CA2912993A1 (en) | 2013-05-24 | 2014-11-27 | Nestec S.A. | Pathway specific markers for diagnosing irritable bowel syndrome |
| EP3078744B1 (en) * | 2013-12-04 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
-
2014
- 2014-05-22 CA CA2912993A patent/CA2912993A1/en not_active Abandoned
- 2014-05-22 CN CN201480041527.7A patent/CN105579852B/zh not_active Expired - Fee Related
- 2014-05-22 AU AU2014269961A patent/AU2014269961A1/en not_active Abandoned
- 2014-05-22 SG SG11201509371XA patent/SG11201509371XA/en unknown
- 2014-05-22 RU RU2015155552A patent/RU2015155552A/ru unknown
- 2014-05-22 JP JP2016514524A patent/JP2016520199A/ja active Pending
- 2014-05-22 SG SG11201509370UA patent/SG11201509370UA/en unknown
- 2014-05-22 WO PCT/IB2014/061636 patent/WO2014188378A1/en not_active Ceased
- 2014-05-22 AU AU2014269960A patent/AU2014269960B2/en not_active Ceased
- 2014-05-22 WO PCT/IB2014/061634 patent/WO2014188377A2/en not_active Ceased
- 2014-05-22 BR BR112015029320A patent/BR112015029320A8/pt not_active Application Discontinuation
- 2014-05-22 EP EP14728346.9A patent/EP3004892B1/en not_active Not-in-force
- 2014-05-22 CN CN201480041536.6A patent/CN105392780A/zh active Pending
- 2014-05-22 MX MX2015016196A patent/MX367046B/es active IP Right Grant
- 2014-05-22 CA CA2913108A patent/CA2913108A1/en not_active Abandoned
- 2014-05-22 RU RU2015155590A patent/RU2015155590A/ru not_active Application Discontinuation
- 2014-05-22 HK HK16111564.5A patent/HK1223361A1/zh unknown
- 2014-05-22 EP EP14731062.7A patent/EP3004068A2/en not_active Withdrawn
- 2014-05-22 KR KR1020157036482A patent/KR20160010621A/ko not_active Ceased
- 2014-05-22 KR KR1020157036487A patent/KR20160013163A/ko not_active Ceased
- 2014-05-22 JP JP2016514523A patent/JP2016521683A/ja active Pending
- 2014-05-22 BR BR112015029318A patent/BR112015029318A2/pt not_active Application Discontinuation
-
2015
- 2015-11-11 US US14/938,710 patent/US9891235B2/en not_active Expired - Fee Related
- 2015-11-11 US US14/938,729 patent/US9739786B2/en not_active Expired - Fee Related
- 2015-11-15 IL IL242597A patent/IL242597B/en not_active IP Right Cessation
- 2015-11-15 IL IL242595A patent/IL242595B/en not_active IP Right Cessation
-
2017
- 2017-07-11 US US15/646,838 patent/US10036759B2/en active Active
- 2017-12-19 US US15/847,406 patent/US20180136233A1/en not_active Abandoned
-
2018
- 2018-06-29 US US16/024,183 patent/US10338083B2/en active Active
- 2018-08-09 AU AU2018214104A patent/AU2018214104A1/en not_active Abandoned
-
2019
- 2019-04-10 JP JP2019075081A patent/JP2019151637A/ja active Pending
- 2019-06-04 JP JP2019104805A patent/JP2019194600A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
| MY194686A (en) | Detection of chromosome interactions | |
| WO2014028884A3 (en) | Cancer diagnostics using biomarkers | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| MX2021006791A (es) | Metodos y composiciones para detectar proteinas mal plegadas. | |
| MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| MX360479B (es) | Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs. | |
| EA201500080A1 (ru) | Способ in vitro диагностирования и мониторинга рака | |
| MX2016004167A (es) | Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal. | |
| WO2015164747A8 (en) | Methods for diagnosing celiac disease using circulating cytokines/chemokines | |
| MX2017000840A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer. | |
| MX2016014769A (es) | Dispositivo de diagnostico a base de orina, flexible, integrado. | |
| WO2015073896A3 (en) | Biomarkers for psma targeted therapy for prostate cancer | |
| MX358474B (es) | Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. | |
| MX386919B (es) | Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática. | |
| EA201790696A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности | |
| MX2016009450A (es) | Ensayo novedoso para detectar periostina humana. | |
| MX377026B (es) | Biomarcadores para la progresión de enfermedades en melanoma. | |
| WO2015077342A3 (en) | Detection of arginine methylation of egfr for prediction of resistance to therapy | |
| GB2552271A (en) | A method for diagnosing lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |